Loading clinical trials...
Loading clinical trials...
Recent drug improvement (e.g. abiraterone or enzalutamide) for castration resistant prostate cancer (CRPC) patients has improved survival. As treatment strategies improve and patients live longer, pat...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Hospital, Ghent
NCT06844383 · Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
NCT05919264 · Cancer, Colorectal Cancer, and more
NCT06615752 · Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06334120 · Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer
NCT07504003 · Endurance Exercise, Healthy Volunteers
University Hospital ghent
Ghent, Oost-Vlaanderen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions